본문으로 건너뛰기
← 뒤로

Dose-Response Relationship Between BRAF V600E Abundance and Cervical Lymph Node Metastasis in Papillary Thyroid Cancer.

Cancers 2025 Vol.17(21)

Yalikun Y, Shen Y, Mao A, Zhou Q, Wei J, Zhu Y, Long M

📝 환자 설명용 한 줄

: Papillary thyroid carcinoma (PTC) frequently presents with cervical lymph node metastasis (CLNM), yet preoperative tools often encode BRAF V600E as a binary variable, potentially overlooking informa

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Yalikun Y, Shen Y, et al. (2025). Dose-Response Relationship Between BRAF V600E Abundance and Cervical Lymph Node Metastasis in Papillary Thyroid Cancer.. Cancers, 17(21). https://doi.org/10.3390/cancers17213562
MLA Yalikun Y, et al.. "Dose-Response Relationship Between BRAF V600E Abundance and Cervical Lymph Node Metastasis in Papillary Thyroid Cancer.." Cancers, vol. 17, no. 21, 2025.
PMID 41228353

Abstract

: Papillary thyroid carcinoma (PTC) frequently presents with cervical lymph node metastasis (CLNM), yet preoperative tools often encode BRAF V600E as a binary variable, potentially overlooking information contained in mutation abundance. We sought to quantify the dose-response relationship between BRAF V600E abundance and CLNM and to develop an interpretable model for preoperative risk stratification. : We performed a single-center retrospective study of consecutive PTC patients who underwent preoperative BRAF V600E testing and surgery from 2019 to 2023. Patients were randomly split 70/30 into training and test sets. Candidate predictors included clinical and ultrasound features and BRAF V600E abundance. We used multivariable logistic regression and restricted cubic splines (RCS) to assess nonlinearity and compared six machine-learning algorithms (LR, KNN, SVM, XGB, LightGBM, and NN). Model performance was evaluated by F1, AUC, calibration, and decision-curve analyses; SHAP aided interpretation. Ethics approval: SYSKY-2024-169-01. : The cohort included 667 patients; CLNM occurred in 391 (58.6%). CLNM cases had higher BRAF abundance (median 23% vs. 17%) and characteristic clinical/sonographic differences. RCS revealed a nonlinear association between abundance and CLNM, with a steep risk rise of up to ~20.7% followed by a plateau. Among six algorithms, XGBoost showed the best validation performance (AUC 0.752; F1 0.73). SHAP indicated that maximum tumor diameter, BRAF abundance, age, and microcalcifications contributed most to predictions. : Modeling BRAF V600E as a quantitative abundance-rather than a binary status-improves preoperative CLNM risk assessment in PTC. An interpretable XGBoost model integrating abundance with routine features demonstrates acceptable discrimination and potential clinical utility for individualized surgical planning and counseling.